Incyte acquires Vega Therapeutics for up to $2B to add late‑phase bleeding‑disorder asset VGA039

Incyte has announced a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for up to $2 billion, including $1.25 billion upfront and up to $750 million in sales‑linked milestones, to add the late‑phase bleeding‑disorder asset VGA039 to its hematology portfolio.

VGA039 is a first‑in‑class monoclonal antibody in Phase 3 pivotal development for von Willebrand disease (VWD), the most common inherited bleeding disorder, and is being evaluated as a potential subcutaneous, convenient‑dosing prophylactic therapy that could expand prophylaxis use in VWD and other bleeding disorders.

The deal is the first major acquisition under new Incyte CEO Bill Meury, who aims to diversify the pipeline ahead of the 2028 patent expiration of Jakafi (ruxolitinib), and the transaction is expected to close in the third quarter of 2026 subject to Hart‑Scott‑Rodino review and other customary conditions.